Natural killer cells and bone marrow mesenchymal stem cells: A dangerous liaison in multiple myeloma

Natural killer cells and bone marrow mesenchymal stem cells: A dangerous liaison in multiple myeloma

Bibliographic Details
Main Authors:	Iria Fernandez Botana, Etienne Moussay, Jérôme Paggetti
Format:	Article
Language:	English
Published:	Wiley 2022-09-01
Series:	Clinical and Translational Discovery
Subjects:	BM‐MSC immune checkpoint blockade NK cells TIGIT
Online Access:	https://doi.org/10.1002/ctd2.116

Similar Items

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies
by: Md Faqrul Hasan, et al.
Published: (2023-05-01)

MicroRNA Regulation of Bone Marrow Mesenchymal Stem Cells in the Development of Osteoporosis in Obesity
by: Maria Vulf, et al.
Published: (2022-06-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells
by: Zhaoyun Liu, et al.
Published: (2023-05-01)

TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
by: Anastasia Tsakmaklis, et al.
Published: (2023-11-01)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
by: Franziska Brauneck, et al.
Published: (2021-11-01)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)

Dracunculin Inhibits Adipogenesis in Human Bone Marrow-Derived Mesenchymal Stromal Cells by Activating AMPK and Wnt/β-Catenin Signaling
by: Fatih Karadeniz, et al.
Published: (2022-01-01)

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
by: Xiu-Man Zhou, et al.
Published: (2018-11-01)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
by: Sophie Rovers, et al.
Published: (2022-03-01)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
by: Hui Peng, et al.
Published: (2022-12-01)

Multimodal Approaches for Regenerative Stroke Therapies: Combination of Granulocyte Colony-Stimulating Factor with Bone Marrow Mesenchymal Stem Cells is Not Superior to G-CSF Alone
by: Adrian Tudor Balseanu, et al.
Published: (2014-06-01)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
by: Negar Hosseinkhani, et al.
Published: (2021-09-01)

Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy
by: Cariad eChester, et al.
Published: (2015-12-01)

Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis
by: Maria Teresa Palano, et al.
Published: (2021-12-01)

Bone marrow-derived mesenchymal stem cells mitigate chronic colitis and enteric neuropathy via anti-inflammatory and anti-oxidative mechanisms
by: Rhian Stavely, et al.
Published: (2024-03-01)

The landscape of TIGIT target and clinical application in diseases
by: Shu Rui, et al.
Published: (2022-09-01)

Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway
by: Jing Yue, et al.
Published: (2023-12-01)

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
by: Beatriz Sanchez-Correa, et al.
Published: (2019-06-01)

Phlorofucofuroeckol A from Edible Brown Alga <i>Ecklonia</i> <i>Cava</i> Enhances Osteoblastogenesis in Bone Marrow-Derived Human Mesenchymal Stem Cells
by: Jung Hwan Oh, et al.
Published: (2019-09-01)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
by: Zhaoyun Liu, et al.
Published: (2023-11-01)

Natural killer cells: the next wave in cancer immunotherapy
by: Xin Chen, et al.
Published: (2022-07-01)

Loliolide from <i>Artemisia princeps</i> Suppresses Adipogenesis in Human Bone Marrow-Derived Mesenchymal Stromal Cells via Activation of AMPK and Wnt/β-catenin Pathways
by: Jung Hwan Oh, et al.
Published: (2021-06-01)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
by: Christian Sordo-Bahamonde, et al.
Published: (2023-08-01)

Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
by: Irina Buckle, et al.
Published: (2021-08-01)

Sphingomyelin is a prospective metabolic immune checkpoint for natural killer cells
by: Hongdi Ma, et al.
Published: (2023-09-01)

Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer
by: Shivan Sivakumar, et al.
Published: (2021-04-01)

Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma
by: Yu Lu, et al.
Published: (2024-03-01)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
by: Shuxin Huang, et al.
Published: (2022-11-01)

Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
by: Jack G. Fisher, et al.
Published: (2022-11-01)

Natural Born Killers: NK Cells in Cancer Therapy
by: S. Elizabeth Franks, et al.
Published: (2020-07-01)

Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
by: Yuhang Fang, et al.
Published: (2022-10-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
by: Daijun Wang, et al.
Published: (2022-03-01)

Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia
by: Iria Fernandez Botana, et al.
Published: (2023-12-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

Peptide-based PET imaging agent of tumor TIGIT expression
by: Dinghu Weng, et al.
Published: (2023-05-01)

Relative expression of receptors in uterine natural killer cells compared to peripheral blood natural killer cells
by: Nurul Izza Ismail
Published: (2023-03-01)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
by: Laszlo Szereday, et al.
Published: (2021-11-01)